Anzeige
Mehr »
Login
Freitag, 17.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
398 Leser
Artikel bewerten:
(2)

Carr's Hill Partners: Carr's Hill Promotes Michael Gude to Vice President and Welcomes Andrew Kern as Senior Associate

Finanznachrichten News

NEW ORLEANS, LA / ACCESSWIRE / August 8, 2023 / Carr's Hill Capital Partners Management, LP ("CHP") is pleased to announce the promotion of Michael Gude to Vice President and the addition of Andrew Kern as a Senior Associate to the firm. These strategic appointments reflect CHP's commitment to nurturing talent and expanding its investment team and capabilities.

Carr's Hill Partners

Carr's Hill Partners



Mr. Gude, previously serving as an Associate of the firm, has been promoted to Vice President. His exceptional contributions to CHP's success over the past three years have been instrumental in creating value throughout our portfolio. Mr. Gude's well-deserved promotion is a testament to his exemplary leadership and embodiment of the firm's core values. Mr. Gude's current portfolio company responsibilities include Axis Industries, Arrow Waste, and Matthews Brothers Dredging. Prior to CHP, Mr. Gude began his career in investment banking at Capital One and received a B.S. in Finance from the College of Charleston.

"Michael has been an integral part of our team since his arrival and has played a vital role in the growth and development of our portfolio. We take great pleasure in acknowledging Michael's well-deserved promotion," added H. David de Laureal, Managing Partner of CHP.

Additionally, CHP welcomes Andrew Kern as a Senior Associate to the investment team. Mr. Kern's responsibilities will include evaluating new investment opportunities, conducting transaction due diligence, and managing the portfolio. With prior experience as an Associate at Stronghold Investment Management, a private equity firm specializing in real assets, and at OFS Energy Fund, a private equity firm focused on the oilfield services sector, Mr. Kern brings a wealth of knowledge to his new role. Mr. Kern started his career in investment banking in Credit Suisse's Global Industrials investment banking group, specializing in the Diversified Industrials and Aerospace & Defense sub-sectors. Mr. Kern holds a B.S. in Commerce from the McIntire School of Commerce at the University of Virginia.

"We are thrilled to have Andrew join our team at such a pivotal time, considering the growth of our current portfolio and the promising investment pipeline," said H. David de Laureal. "His return to his hometown of New Orleans and his significant contributions to the growth of Carr's Hill make this an exciting time for him and the team."

About Carr's Hill Partners
Carr's Hill Partners is a lower middle-market private equity firm that provides capital and expertise to family & founder-owned industrial companies. Based in New Orleans, CHP invests throughout North America, focusing on the Southern United States. The firm's operating expertise, institutional capabilities, and network of executives provide management partners with a foundation for exceptional growth. For more information, visit: www.carrshillpartners.com.

Contact Information

Travis Rachal
travis@carrshillpartners.com
(504) 334-8754

SOURCE: Carr's Hill Partners

.

View source version on accesswire.com:
https://www.accesswire.com/772726/Carrs-Hill-Promotes-Michael-Gude-to-Vice-President-and-Welcomes-Andrew-Kern-as-Senior-Associate

© 2023 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.